Sanjay Kulkarni, MD, FACS, BS

Associate Professor of Surgery (Transplant) and of Medicine (Nephrology); Medical Director, Center for Living Organ Donors; Scientific Director, Yale Transplant Research Unit; Surgical Director, Kidney & Pancreas Transplantation

Clinical Interests

  • Behavioral Disciplines and Activities
  • Environment and Public Health
  • Surgical Procedures, Operative
  • Therapeutics

Patient Care

Accepts new patients? Yes
Patient Type: Adult; Adolescent; Child
Referrals: From patients or physicians

Patient Care Organizations

Surgery: Transplant & Immunology


Cancer Center

Liver Center

Transplantation Center

Yale Medicine

Office of Cooperative Research

Board Certifications

  • Surgery, General AB of Surgery (2003)

Clinical Trials

Conditions Study Title
Diseases of the Kidney & Urinary Tract, Men's Health, Women's Health Evaluation of Acute Rejection Rates in de Novo Renal Transplant Recipients Following Thymoglobulin Induction, CNI-free, Nulojix (Belatacept)-Based Immunosuppression
Diseases of the Kidney & Urinary Tract, Men's Health, Women's Health Effects of Inhibiting Early Inflammation in Kidney Transplant Patients
Diseases of the Kidney & Urinary Tract A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based

Edit this profile

Contact Info

Sanjay Kulkarni, MD, FACS, BS
Patient Care Locations
Yale Heart Failure and Transplant Saint Francis Care
1000 Asylum Avenue, Ste Suite 3201F

Hartford, CT 06105
View on map...
Yale-New Haven Transplantation CenterYale Physicians Building
800 Howard Avenue, Ste 3rd floor

New Haven, CT 06519
View on map...
Yale Transplant & ImmunologyFarnam Memorial Building
310 Cedar Street

New Haven, CT 06510
View on map...
Mailing Address
PO Box 208062
New Haven, CT 06520-8062

Curriculum Vitae

Eculizumab for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients

Graph shows all clinical trial patients randomized to the treatment arm. Treatment patients received 6 months of eculizumab treatment followed by 6 months of observation.